Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study.
作者： G A Omura , B N Bundy , J S Berek , S Curry , G Delgado
关键词:
摘要: … There was no difference in outcome comparing those who refused second-look with those who had a second-look. …
sci-hub.se 参考文章(21)
David R. Cox, Regression Models and Life-Tables Springer Series in Statistics. ,vol. 34, pp. 527- 541 ,(1992) , 10.1007/978-1-4612-4380-9_37
PF Conte, M Bruzzone, S Chiara, MR Sertoli, MG Daga, A Rubagotti, A Conio, M Ruvolo, R Rosso, L Santi, None, A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer. Journal of Clinical Oncology. ,vol. 4, pp. 965- 971 ,(1986) , 10.1200/JCO.1986.4.6.965
E. L. Kaplan, Paul Meier, Nonparametric Estimation from Incomplete Observations Springer Series in Statistics. ,vol. 53, pp. 319- 337 ,(1992) , 10.1007/978-1-4612-4380-9_25
George Omura, John A. Blessing, Clarence E. Ehrlich, Alexander Miller, Edgardo Yordan, William T. Creasman, Howard D. Homesley, A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group Study. Cancer. ,vol. 57, pp. 1725- 1730 ,(1986) , 10.1002/1097-0142(19860501)57:9<1725::AID-CNCR2820570903>3.0.CO;2-J
Robert C. Young, Robert F. Ozols, Charles E. Myers, The anthracycline antineoplastic drugs. The New England Journal of Medicine. ,vol. 305, pp. 139- 153 ,(1981) , 10.1056/NEJM198107163050305
K. Bertelsen, A. Jakobsen, J.E. Andersen, S. Ahrons, P.Hjortkjær Pedersen, H. Kiær, E. Arffmann, P. Bichel, E. Boestofte, I.Strøyer Christophersen, E. Gregersen, M.Kern Hansen, B. Hølund, M. Jacobsen, H.Kaalund Jensen, F.Løve Jepsen, G. Larsen, E.Sandberg Nielsen, M. Nyland, J. Olsen, J. Panduro, F. Rank, A. Sell, H. Søgaard, A randomized study of cyclophosphamide and cis-platinum with or without doxorubicin in advanced ovarian carcinoma Gynecologic Oncology. ,vol. 28, pp. 161- 169 ,(1987) , 10.1016/0090-8258(87)90210-1
Lawrence V. Rubinstein, Mitchell H. Gail, Thomas J. Santner, Planning the duration of a comparative clinical trial with loss to follow-up and a period of continued observation Journal of Chronic Diseases. ,vol. 34, pp. 469- 479 ,(1981) , 10.1016/0021-9681(81)90007-2
Frank M. Schabel, Rationale for adjuvant chemotherapy Cancer. ,vol. 39, pp. 2875- 2882 ,(1977) , 10.1002/1097-0142(197706)39:6<2875::AID-CNCR2820390675>3.0.CO;2-7
G BARKER, RANDOMISED TRIAL COMPARING LOW-DOSE CISPLATIN AND CHLORAMBUCIL WITH LOW-DOSE CISPLATIN, CHLORAMBUCIL, AND DOXORUBICIN IN ADVANCED OVARIAN CARCINOMA The Lancet. ,vol. 317, pp. 747- 750 ,(1981) , 10.1016/S0140-6736(81)92625-8
Howard W. Bruckner, Carmel J. Cohen, Judith D. Goldberg, Bernard Kabakow, Robert C. Wallach, Gunter Deppe, Ezra M. Greenspan, Saul B. Gusberg, James F. Holland, Improved chemotherapy for ovarian cancer with cis-diamminedichloroplatinum and adriamycin Cancer. ,vol. 47, pp. 2288- 2294 ,(1981) , 10.1002/1097-0142(19810501)47:9<2288::AID-CNCR2820470931>3.0.CO;2-3